Xilio Therapeutics, Inc. (XLO) Stock price, Description, News & Info

#Thinksabio latest news

Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting